Intranasal Insulin Treatment for Weight Management During Smoking Cessation

戒烟期间用于体重管理的鼻内胰岛素治疗

基本信息

项目摘要

DESCRIPTION (provided by applicant): Weight gain following smoking cessation has been associated with increased risk of relapse to smoking as well as development of diabetes. To date, there are no clinical treatments that target weight gain caused by smoking cessation. This project proposes to test efficacy of intranasal insulin treatment in controlling behavioral and metabolic aspects of food intake. Thus far, intranasal insulin treatment has demonstrated an exceptional safety profile, and preliminary data indicate that it has benefits on weight-related parameters. Intranasal administration delivers insulin directly to the Central Nervous System, without a significant peripheral absorption that would cause hypoglycemic events. Intranasal insulin reduces snacking as well as circulating free fatty acids - metabolites that significantly contribute to the development of diabetes. This is a Phase II, human experimental study with a specific objective to provide efficacy data for a larger Phase III trial of intranasal insulin treatment during smoking cessation. Subjects in this study will participate in two sessions in which they will receive intranasal insulin and placebo. After eating breakfast, their circulating free fatty acids will be assessed. We hypothesize lower free fatty acids in the intranasal insulin vs. placebo condition. Two and a half hours after lunch, subjects will participate in a mock taste test. They will be told that the objective is to rate palatability of three different kinds of cookes. Following the ratings, subjects will be told that the remainder of cookies will be discarded and that they are free to eat however much they would like. We hypothesize that the cookie consumption in the treatment (intranasal insulin) condition will be lower in comparison to the placebo condition. Milestones for this project include demonstrating intranasal insulin's benefit on satiety and metabolic profile during nicotine withdrawal.
描述(由申请人提供):戒烟后体重增加与吸烟复发风险增加以及糖尿病发展相关。到目前为止,还没有针对戒烟引起的体重增加的临床治疗方法。该项目旨在测试鼻内胰岛素治疗在控制食物摄入的行为和代谢方面的功效。到目前为止,鼻内胰岛素治疗已证明了一个特殊的安全性,初步数据表明,它对体重相关参数的好处。鼻内给药将胰岛素直接递送至中枢神经系统,而没有会引起低血糖事件的显著外周吸收。鼻内胰岛素减少零食以及循环游离脂肪酸-代谢产物,显着促进糖尿病的发展。这是一项II期人体实验研究,其特定目的是为戒烟期间鼻内胰岛素治疗的更大III期试验提供疗效数据。本研究中的受试者将参加两个阶段,期间他们将接受鼻内胰岛素和安慰剂治疗。吃早餐后,将评估他们的循环游离脂肪酸。我们假设鼻内胰岛素与安慰剂相比游离脂肪酸较低。午餐后两个半小时,受试者将参加模拟味觉测试。他们将被告知,目的是评价三种不同种类的厨师的适口性。在评级之后,受试者将被告知剩余的饼干将被丢弃,他们可以自由地吃他们想吃的东西。我们假设治疗(鼻内胰岛素)条件下的饼干消耗量低于安慰剂条件。该项目的重要性包括证明鼻内胰岛素在尼古丁戒断期间对饱腹感和代谢特征的益处。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ajna Hamidovic其他文献

Ajna Hamidovic的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ajna Hamidovic', 18)}}的其他基金

Late Luteal Phase Reactivity to Stress
黄体后期对应激的反应
  • 批准号:
    9895083
  • 财政年份:
    2019
  • 资助金额:
    $ 7.44万
  • 项目类别:
Late Luteal Phase Reactivity to Stress
黄体后期对应激的反应
  • 批准号:
    10057230
  • 财政年份:
    2019
  • 资助金额:
    $ 7.44万
  • 项目类别:
Intranasal Insulin Treatment for Weight Management During Smoking Cessation
戒烟期间用于体重管理的鼻内胰岛素治疗
  • 批准号:
    8772450
  • 财政年份:
    2014
  • 资助金额:
    $ 7.44万
  • 项目类别:
Efficacy of Intranasal Insulin in Relieving Symptoms of Tobacco Abstinence Syndro
鼻内胰岛素缓解戒烟综合症症状的功效
  • 批准号:
    8702860
  • 财政年份:
    2014
  • 资助金额:
    $ 7.44万
  • 项目类别:
Genetic Variation in Amphetamine Response
安非他明反应的遗传变异
  • 批准号:
    7483842
  • 财政年份:
    2008
  • 资助金额:
    $ 7.44万
  • 项目类别:
Genetic Variation in Amphetamine Response
安非他明反应的遗传变异
  • 批准号:
    7659565
  • 财政年份:
    2008
  • 资助金额:
    $ 7.44万
  • 项目类别:

相似海外基金

Prapela™ SVS: A cost-effective stochastic vibrotactile stimulation device toimprove the clinical course of infants with neonatal abstinence syndrome.
Prapela™ SVS:一种经济高效的随机振动触觉刺激装置,可改善患有新生儿戒断综合征的婴儿的临床过程。
  • 批准号:
    10837421
  • 财政年份:
    2023
  • 资助金额:
    $ 7.44万
  • 项目类别:
Understanding the miRNA response to opioid withdrawal and their uses as potential biomarkers for neonatal abstinence syndrome
了解 miRNA 对阿片类药物戒断的反应及其作为新生儿戒断综合征潜在生物标志物的用途
  • 批准号:
    10536908
  • 财政年份:
    2022
  • 资助金额:
    $ 7.44万
  • 项目类别:
Longitudinal Academic Performance in Children with a History of Neonatal Abstinence Syndrome
有新生儿戒断综合症病史的儿童的纵向学业表现
  • 批准号:
    10349927
  • 财政年份:
    2022
  • 资助金额:
    $ 7.44万
  • 项目类别:
Longitudinal Academic Performance in Children with a History of Neonatal Abstinence Syndrome
有新生儿戒断综合症病史的儿童的纵向学业表现
  • 批准号:
    10608149
  • 财政年份:
    2022
  • 资助金额:
    $ 7.44万
  • 项目类别:
Which elements contribute to building effective collaborations to promote health system culture and practice change towards improved care for mothers and babies with Neonatal Abstinence Syndrome?
哪些要素有助于建立有效的合作,以促进卫生系统文化和实践变革,从而改善对患有新生儿戒断综合症的母亲和婴儿的护理?
  • 批准号:
    465827
  • 财政年份:
    2022
  • 资助金额:
    $ 7.44万
  • 项目类别:
    Fellowship Programs
Examining the Implementation of the Eat, Sleep, Console Model of Care for Infants with Neonatal Abstinence Syndrome in Nova Scotia
检查新斯科舍省新生儿戒断综合症婴儿的饮食、睡眠、控制台护理模式的实施情况
  • 批准号:
    474575
  • 财政年份:
    2022
  • 资助金额:
    $ 7.44万
  • 项目类别:
    Studentship Programs
Effective Caregiving for Neonatal Abstinence Syndrome: Development of an Instructional Mobile Technology Platform for High-Risk Pregnant Women
新生儿禁欲综合症的有效护理:为高危孕妇开发教学移动技术平台
  • 批准号:
    10321503
  • 财政年份:
    2021
  • 资助金额:
    $ 7.44万
  • 项目类别:
Wireless withdrawal detection and monitoring system for neonatal abstinence syndrome.
新生儿戒断综合征无线戒断检测和监测系统。
  • 批准号:
    10013069
  • 财政年份:
    2020
  • 资助金额:
    $ 7.44万
  • 项目类别:
Effective Caregiving for Neonatal Abstinence Syndrome: Development of an Instructional Mobile Technology Platform for High-Risk Pregnant Women
新生儿禁欲综合症的有效护理:为高危孕妇开发教学移动技术平台
  • 批准号:
    10039798
  • 财政年份:
    2020
  • 资助金额:
    $ 7.44万
  • 项目类别:
Wireless withdrawal detection and monitoring system for neonatal abstinence syndrome.
新生儿戒断综合征无线戒断检测和监测系统。
  • 批准号:
    10304777
  • 财政年份:
    2020
  • 资助金额:
    $ 7.44万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了